Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. (clinicaltrials.gov) - Aug 29, 2025 - P2 | N=12 | Terminated | Sponsor: Alaunos Therapeutics | The SRC reduced 140 mg to 100 mg, then to 80 mg. The study ended with one subject enrolled at 80 mg daily.
Monotherapy • Trial termination • Breast Cancer • Oncology • Solid Tumor • IL12A • MUC1
|